AlloCure Pockets $25M for Acute Kidney Injury Stem Cell Therapy
Genetic Engineering News
The company is developing AC607, an allogeneic mesenchymal stem cell therapy, for acute kidney injury (AKI) and believes that the funding will allow it to complete Phase II trials. “A treatment for AKI is an important unmet medical need, recognized by ...
AlloCure Raises $25 Million Series B Venture FinancingEON: Enhanced Online News (press release)
Lundbeckfond leads $25M B round for AlloCure's Phase II stem cell studyFierceBiotech
AlloCure raises $25M round for kidney disease trialMass High Tech

all 18 news articles »